Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762258 | 1.00 | LMNA (0.40) | LMNAGAAPOLBMCL1HDAC3 | |
| SCHEMBL27262796 | 1.00 | LMNA (0.40) | LMNAGAAPOLBMCL1HDAC3 | |
| SCHEMBL27262127 | 1.00 | LMNA (0.40) | LMNAGAAPOLBMCL1HDAC3 | |
| SCHEMBL15987189 | 0.98 | LMNA (0.41) | LMNAGAAPOLBMCL1HDAC3 | |
| SCHEMBL27347790 | 0.89 | LMNA (0.48) | LMNAGAAPOLBMCL1MEN1 | |
| SCHEMBL16280975 | 0.89 | LMNA (0.48) | LMNAGAAPOLBMCL1MEN1 | |
| SCHEMBL22787027 | 0.87 | LMNA (0.50) | LMNAGAAPOLBMCL1MEN1 | |
| SCHEMBL20647706 | 0.86 | LMNA (0.39) | LMNAGAAHDAC3HDAC1KMT2A | |
| SCHEMBL30678645 | 0.83 | LMNA (0.40) | LMNAGAAPOLBMCL1MEN1 | |
| SCHEMBL8520494 | 0.83 | LMNA (0.31) | LMNAPOLBMCL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020163594-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-13 | — | — | WO | disclosed |
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | LMNA 4842/4885GAA 3185/4885POLB 2398/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | LMNA 4851/4885GAA 3205/4885POLB 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.